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Background: Candida glabrata is a common non-albicans Candida species found in patients with 
candidiasis and it sometimes develops antifungal resistance. Human beta-defensin-3 (hBD-3) is 
an antimicrobial peptide of immune system active against various types of microbes including 
Candida spp. 
Objectives: To investigate antifungal activity of hBD-3 and its synergistic effect with a first-line 
antifungal agent on clinical isolates of C. glabrata.  
Methods: Candida spp. were characterised in patients with candidiasis. The antifungal activities 
of hBD-3 and fluconazole against C. glabrata were evaluated using Broth microdilution assay. 
The synergistic activity of these two agents was determined by checkerboard microdilution and 
time-killing assays. The cytotoxicity of hBD-3 was evaluated using LDH-cytotoxicity colorimetric 
assay. 
Results: Of 307 episodes from 254 patients diagnosed with candidiasis, C. glabrata was found in 
21 clinical isolates. Antifungal susceptibility tests of C. glabrata were performed, fluconazole 
demonstrated an inhibitory effect at concentrations of 0.25-8 µg/ml but one antifungal resistant 
strain was identified (>64 µg/ml). hBD-3 showed an inhibitory effect against all selected strains at 
concentrations of 50-75 µg/ml and exhibited a synergistic effect with fluconazole at the fractional 
inhibitory concentration index (FICI) of 0.25-0.50. A concentration of 25 μg/ml of hBD-3 alone 
showed no cytotoxicity but synergistic activity was seen with fluconazole.  
Conclusion: hBD-3 has antifungal activity against C. glabrata and synergistic effects with 
fluconazole at concentrations that alone, have no cytotoxicity. hBD-3 could be used as an 
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adjunctive therapy with first-line antifungal agents for patients with C. glabrata infection 
particularly those infected with fluconazole-resistant strains. 
 
Introduction 
Candidiasis is a frequent healthcare-associated infection and is widely recognized as a 
major opportunistic infection in patients with chronic diseases and immunodeficiency (Lockhart, 
2014; McCarty, Pappas, 2016; Pappas et al., 2018). Candida albicans is the most common species 
found in these patients with candidiasis. However, recent studies have shown that non-albicans 
Candida spp. have been significantly increasing worldwide, particularly Candida glabrata 
(Diekema et al., 2012; Guinea, 2014; Tan et al., 2015). It has been reported that C. glabrata is the 
first or second most common non-albicans Candida spp., and it has a remarkable capacity to 
develop drug resistance to currently used antifungal agents (e.g. fluconazole) (Arendrup, Patterson, 
2017; Healey et al., 2016; Pappas et al., 2018; Vale-Silva, Sanglard, 2015). Patients with 
candidiasis caused by C. glabrata shows higher morbidity than those infected with different 
Candida spp. (Kullberg, Arendrup, 2015). Therefore, many studies have been searching for novel 
strategies to improve the current treatment against C. glabrata. One area of research interest is a 
possible use of current antifungal agents combined with other antimicrobial agents such as human 
antimicrobial peptides (AMPs) (Hancock et al., 2016; Silva et al., 2014). 
Human AMPs, also known as host defense peptides, are short cationic amphipathic 
peptides with diverse sequences produced by various types of immune cells (Hancock et al., 2016). 
These peptides demonstrate a wide range of activities not only in eliminating pathogens (e.g. 
bacteria, virus and fungi), but also in modulating immune functions of host cells and tissues. The 
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structure of AMPs provides an overall net positive charge that targets the negative charges on the 
microbial surface with electrostatic interactions leading to pore formation and disruption of the 
microbial cell membrane (Bobone, 2014; Scorzoni et al., 2017; Silva et al., 2014).  
There are several types of human AMPs such as cathelicidin (LL-37), psoriasin (S100A7), 
dermcidin and defensins (Pazgier et al., 2006; Wang, 2014). Human b-defensins (hBDs), a type of 
defensin family, are composed of 4 different subtypes. hBDs are mainly produced by epithelial 
cells lining on the skin, airways, gastrointestinal and genitourinary tracts (Pazgier et al., 2006; 
Wang, 2008). It has been demonstrated that hBD-3 has the highest positive charge (+11) and this 
subtype shows a broad range of killing pathogens including bacteria, viruses, and fungi including 
Candida spp. (Hancock et al., 2016; Wang, 2014).  
This study therefore aimed to investigate the effect of hBD-3 alone and in combination 
with fluconazole on C. glabrata, including a drug resistant strain, isolated from patients with C. 
glabrata infection. 
 
Materials and Methods 
The following reagents were used in this study: human beta-defensin-3 (Peptide Institute, 
Japan); fluconazole, MOPS 3-(N-Morpholino) propane sulfonic acid buffer, fibronectin, bovine 
serum albumin (Sigma-Aldrich, USA); RPMI 1640 media with glutamine and phenol red,  bovine 
collagen type I (Gibco, USA); yeast extract (Lab-M, UK); bacteriological peptone, dextrose 
bacteriological grade and sabouraud dextrose agar (Oxoid, UK); chloramphenicol (AcumediaTM, 
USA); cycloheximide (BD BBLTM, USA); agar powder (Himedia, India); bronchial epithelial cell 
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growth medium bullet kit without GA-1000 (Lonza, Switzerland); LDH-cytotoxicity colorimetric 
assay kit II (Biovision Inc, USA). 
Data collection 
We obtained all retrospective data of patient records from the principal diagnosis, 
comorbidity, and complication of identified candidiasis from the Mycology laboratory records at 
the tertiary-care King Chulalongkorn Memorial Hospital (KCMH), from 1 January 2017 to 31 
December 2017. This study was approved by the Institutional Review Board (IRB No. 262/61), 
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. The retrieved data included 
specimen collection date, lab number, age, gender, specimen source, species name, and patient 
diagnosis. Candida spp. isolated from the same patient/location within 7 days were considered as 
species arising from the same infection episode, whilst isolates from patients/samples >7 days after 
the first isolation were considered as distinct episodes of infection. 
Yeast Identification 
All collected specimens were initially examined using 10% KOH (Potassium hydroxide) 
solution under light microscopy. Each specimen was cultured for up to 4 weeks until fungal 
colonies were observed in: Sabouraud dextrose agar (SDA);  SDA with chloramphenicol;  SDA 
with chloramphenicol plus cycloheximide, at both 37 ̊C and 25 ̊C depending on the type of 
specimen. All positive colonies were visualised by light microscopy after lactophenol cotton blue 
staining. Vitek 2® XL (BioMérieux) with YST cards which is an automated colorimetric 
biochemical assay, were used for yeast identification. Detain in brief (Aj Mee) (Posteraro et al., 




C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were used as laboratory quality 
controls (QC) for testing the antifungal drug susceptibility of C. glabrata clinical isolates. The C. 
glabrata S3304, S3650 and F52615 isolates randomly chosen for this study were collected from 
the respiratory tract of patients with candidiasis. The C. glabrata F2018C  isolate from the blood 
of the patients was identified as fluconazole-resistant while the C. glabrata ATCC 2001 strain was 
used as a standard species. All strains and isolates were grown on yeast peptone dextrose agar 
(YPD; 1% w/v yeast extract, 2% w/v peptone, 2% w/v dextrose, 1.5% w/v agar) at 35ºC for 48 h 
prior to experiments. 
Antifungal susceptibility testing  
Stock solutions of fluconazole and hBD-3 were prepared in sterile water and frozen at -
20ºC before use. Final concentrations of fluconazole ranged from 0.125 to 64 μg/ml and hBD-3 
ranged from 0.019 to 100 µg/ml,  diluted in RPMI-1640 media based on the Clinical and 
Laboratory Standards Institute (CLSI) broth microdilution M27-A3 method (Institute, 2017). 
Minimum inhibitory concentrations (MICs) of C. glabrata to fluconazole and hBD-3 were 
measured using the CLSI broth microdilution M27-A3 method (Institute, 2017). The lowest 
concentration of each drug that produced a measurable decrease in turbidity after 24 h incubation 
compared to drug-free growth control were recorded as 50% of MIC. The MIC breakpoints used 
for interpretation of fluconazole were followed by CLSI M27-S4E guidelines: MIC ≤ 32 µg/ml, 
susceptible-dose dependence (S-DD); MIC ≥ 64 µg/ml, resistance (R). All experiments were 
performed in biological triplicates. 
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Fungicidal testing  
Minimum fungicidal concentrations (MFCs) of C. glabrata to hBD-3 were determined 
using the spread plate technique.  Cell suspension of each MIC50 ± 1 concentration was diluted 
and plated onto SDA plates at 35°C for 24 h. The concentrations of the peptides that resulted in no 
viable colonies were recorded as MFCs. All experiments were performed in biological triplicates. 
Checkerboard microdilution assay 
The fractional inhibitory concentration (FIC) between fluconazole and hBD-3 was assessed 
by checkerboard assay according to CLSI broth microdilution M27-A3 method (Institute, 2017) 
(Refs), and recorded visually as for MIC measurements. The FIC index (FICI) was calculated 
using the sum of the FICs of each drug tested. The FIC of each drug was determined using the 
MIC of each drug when used in combination, divided by the MIC of each drug when used alone 
at 24 h. The FICI values were interpreted as follows: FICI ≤ 0.5, synergistic; 0.5 < FICI  £ 1, 
additive; 1 < FICI £ 4, no interaction (indifferent); FICI > 4, antagonistic (Denardi et al., 2017; 
Shrestha et al., 2015b). All experiments were performed in biological triplicates. 
Time-killing assay 
C. glabrata F2018C at 103 cells were incubated in RPMI-1640 medium alone (growth 
control), or medium with 0.5x MIC of fluconazole alone (32 μg/ml), 0.5x MIC of hBD-3 alone 
(25 μg/ml), or a combination between 32 μg/ml  of fluconazole and 25 μg/ml of hBD-3. The yeast 
cell suspensions were incubated at 35°C in 200 rpm shaking incubator. At 0, 4, 8, 12 and 24 h 
incubation, aliquots of 100 μl from each tube were serially diluted and 100 μl of each dilution was 
plated onto SDA plates. Colony counts were determined after 48 h of incubation at 35ºC, and 
assessed according to the following criteria: CFU/ml of combination decrease ≥ 2 log10 compared 
to the most active drug = synergistic; CFU/ml of combination increase ≥ 2 log10 compared to the 
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least active drug = antagonism (Shrestha et al., 2015a; Shrestha et al., 2015b). This experiment 
was performed in three biological triplicates. 
Cell lines and culture 
Human bronchial epithelial BEAS-2B cells (ATCC) were cultured in a pre-coated tissue 
culture flask, as recommended by ATCC (0.01 mg/ml fibronectin, 0.03 mg/ml  bovine collagen 
type I, 0.01 mg/ml bovine serum albumin) with Bronchial Epithelial Cell Growth Medium 
(BEGM) Medium at 37ºC in a 5% CO2 incubator. The cells were serially passaged before reaching 
confluence, and experiments were conducted with subconfluent cells at 3rd-5th passage in the 
proliferative phase at 70–80% confluence. 
Cytotoxicity test 
Cytotoxicity of hBD-3 was measured using the LDH-Cytotoxicity Colorimetric Assay. 
Briefly, 104 BEAS-2B cells were seeded with 50 µl of DMEM in a pre-coated 96-well plates. hBD-
3 at concentrations of 25, 50, 75 and 100 µg/ml were added into the plate and the cells were 
incubated in 5% CO2 incubator at 37ºC for 24 h. The culture medium was collected and transferred 
into a 96 well-plate and incubated with the LDH Reaction Mix for 30 min at room temperature. 
The absorbance of all controls and samples were measured using a 450 nm filter and the percentage 
of cytotoxicity was calculated using the following formula: 




All data were analyzed using GraphPad Prism software version 8. Comparison between 
groups performed with a one-way ANOVA with post-hoc Bonferroni's multiple comparisons test. 
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There were total 307 episodes of candidiasis from 254 patients and C. glabrata accounted 
for 21 episodes from 21 patients (6.8%) (Figure 1). Of patients with C. glabrata infection, 15 
patients were male (71.4%) and 6 patients were female (28.57%). The mean age of the patients 
was 69 ± 16.75 years old (Table 1). The clinical isolates were collected from the respiratory tract, 
skin and nails, urine and blood (Table 2). 
The inhibitory effect of human beta-defensin-3 on the growth of Candida glabrata 
To evaluate the susceptibility to fluconazole of each C. glabrata isolates, the MIC values 
of fluconazole were measured prior to hBD-3 susceptibility tests. Of 21 clinical isolates from 21 
patients, 5 strains were no longer reserved in the laboratory stock during the period of this study. 
Therefore, antifungal susceptibility tests using C. glabrata clinical isolates (n=16) compared to C. 
glabrata ATCC 2001 were performed. This showed that all 16 strains were inhibited by 
fluconazole with the MICs ranging from 1-8 µg/ml (susceptible-dose dependent; S-DD), except 
for one clinical isolate of C. glabrata (F2018C), that showed an MIC of up to 64 µg/ml 
(fluconazole-resistant; R) (Table 3). Nevertheless, most strains of C. glabrata were susceptible to 
the second line antifungal agents; caspofungin and amphotericin B. 
To evaluate the antifungal inhibitory effect of hBD-3, an antifungal susceptibility test was 
performed as for fluconazole. The result showed that hBD-3 inhibited the growth of all randomly 
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chosen C. glabrata isolates with the MICs ranging from 50-75 µg/ml (Table 4). Furthermore, MFC 
of C. glabrata ATCC 2001 was 50 µg/ml while MFCs of both C. glabrata F2018C and S3304 
were 75 µg/ml. However, the MFCs of C. glabrata S3650 and F52615 were > 100 µg/ml. 
The synergistic effect of human beta-defensin-3 and fluconazole on fluconazole-resistant 
Candida glabrata 
As previous experiments showed that hBD-3 inhibited the growth of all chosen isolates of 
C. glabrata at the concentration of 50-75 µg/ml, checkerboard assays were performed and the 
result showed that the MICs of fluconazole decreased to 8 µg/ml and the MICs of hBD-3 were 
6.25 µg/ml  (Figure 2). The fractional inhibitory concentration index (FICI) values ranged from 
0.25 to 0.50. The FICI values suggested that both hBD-3 and fluconazole showed synergistic 
effects on fluconazole-resistant isolates of C. glabrata. 
To confirm this synergistic effect of hBD-3 and fluconazole against fluconazole-resistant 
Candida glabrata, time-killing assays were performed. The time-killing assays revealed that the 
growth of fluconazole-resistant C. glabrata was significantly decreased at 2 log10 in CFU/ml 
compared to single drug treatment and the untreated group (Figure 3). This result confirmed that 
hBD-3 showed a synergistic effect with fluconazole to inhibit the growth of fluconazole-resistant 
C. glabrata. 
Human beta-defensin-3 cytotoxicity towards human cells 
To assess the cytotoxic effect of hBD-3 on human cells, LDH-cytotoxicity colorimetric 
assays were performed. The result demonstrated that hBD-3 at a concentration of 25 μg/ml showed 
no significant cytotoxicity on BEAS-2B when compared with untreated control cells (Figure 4a). 
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Additionally, this cytotoxicity of hBD-3 together with fluconazole at a concentration of 32 μg/ml 
on BEAS-2B was not significantly different to that of  untreated cells (Figure 4b). 
 
Disscussion 
hBDs contain a high content of cationic residues clustered near the carboxyl terminus 
which is essential for their antimicrobial property (Wang, 2014). These cationic residues induce 
electrostatic interactions leading to disruption of the cell membrane of pathogens (Pazgier et al., 
2006). As hBD-3 is a member of the hBD family that contains the highest positive charge even in 
high salt concentrations (+11 net charge) (Wang, 2014) and broad-spectrum antibiotic activity 
(Joly et al., 2004; Krishnakumari et al., 2009; Schneider et al., 2005; Sudheendra et al., 2015),  our 
study first investigated whether hBD-3 inhibited growth of C. glabrata (Pappas et al., 2018; Vale-
Silva, Sanglard, 2015).  
Of all of the Candida spp. isolated from patients with candidiasis at KCMH, C. albicans 
was the most common species found, whilst C. tropicalis and C. glabrata were the leading cause 
of non-albicans Candida infection in our population, which is similar to a previous study (Tan et 
al., 2015). The current treatment of candidiasis, including C. glabrata infections, are azoles (as the 
first choice of treatment), caspofungins or echinocandins; however, their adverse drug reactions 
and side effects need to be carefully considered, particularly in patients with underlying illnesses 
(e.g. renal and liver diseases) (Pappas et al., 2018). Moreover, C. glabrata is capable of developing 
drug resistance to the antifungal agents (Diekema et al., 2012; Pappas et al., 2018; Vale-Silva, 
Sanglard, 2015).  
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In our study, we found that one of the 16 isolates (6.25%) of  C. glabrata was resistant to 
fluconazole. Interestingly, our results demonstrated that hBD-3 showed inhibitory effects against 
all randomly chosen C. glabrata clinical isolates, including this fluconazole-resistant isolate (Table 
4). However, the inhibitory concentrations of hBD-3 on each strain varied (50-75 μg/ml), probably 
due to differences in cell membrane structure that affect the total net charge of C. glabrata 
(Hollmann et al., 2018; Marr et al., 2006). Furthermore, cell wall thickness and other resistance 
mechanisms of C. glabrata (e.g. efflux pump overexpression and drug target alteration) may play 
roles in drug resistance, which resulted in different fungicidal activity of hBD-3 (Arendrup, 
Patterson, 2017; Déry, Hasbun, 2011).  
In order to combat the clinical problems associated with the evolution of drug-resistant 
fungi, many previous studies have demonstrated the efficacy of different combinations of groups 
of antifungal agents or combined with other drugs both in vitro and in vivo in order to increase the 
inhibitory effects on drug-resistant fungi (Campitelli et al., 2017; Scorzoni et al., 2017). For 
instance, combination therapy between azoles or amphotericin B and chemotherapeutic agents 
(e.g. flucytosine) showed synergistic effects on drug-resistant cryptococcosis and candidiasis by 
increasing an uptake of flucytosine, that inhibits nucleic acid synthesis, after cell membrane 
damage (Campitelli et al., 2017; Scorzoni et al., 2017). Furthermore, the combination of azoles 
and some modified antibiotics (e.g. tobramycin and aminoglycosides) that are used to inhibit 
bacterial protein synthesis, and also showed synergistic effects on Candida spp. (Shrestha et al., 
2015a; Shrestha et al., 2015b). As a synergistic effect of azoles combined with hBD-3 has never 
been reported, our study explored this drug combination on fluconazole-resistant C. glabrata 
clinical isolate and found that hBD-3 showed a synergistic effect with fluconazole by reducing the 
MICs of fluconazole and hBD-3 of fluconazole-resistant C. glabrata (Figure 2-3). We propose 
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that hBD-3 may induce cell membrane permeability of C. glabrata, potentially by induction of 
pore formation or micellization on the membrane which then promotes fluconazole intracellular 
uptake (Pasupuleti et al., 2012; Silva et al., 2014). Increased uptake of fluconazole, can then inhibit 
the activity lanosterol 14 alpha-demethylase enzyme which normally converts lanosterol to 
ergosterol on fungal cell membrane: this disruption then alters cell membrane integrity (Berkow, 
Lockhart, 2017; Pappas et al., 2018; Scorzoni et al., 2017). 
In order to measure cytotoxicity of these drugs on human cells, we performed a LDH-
Cytotoxicity Colorimetric Assay to investigate the cytotoxicity of fluconazole, hBD-3 and their 
combination on human bronchial epithelial cells. Although hBD-3 alone had dose-dependent 
cytotoxic effects (Figure 4a), we did not find any cytotoxic activity at the concentration of 
combination drugs that we used, and we found these had a synergistic effect (Figure 4b). Our 
study,  showing this selective cytotoxicty effect on different cells may be explained by differences 
in the proprerties of the target membranes. For example, it may be that hBD-3 (at £ 25 μg/ml with 
or without fluconazole) has an affinity for the negatively charged hydrophobic lipids in the cell 
membrane of C. glabrata that is greater than for the zwitterionic (neutral) amphiphilic components 
on the human cell membrane: this may explain selectivity of hBD-3 for antimicrobial activity 
(Hollmann et al., 2018; Maturana et al., 2017; Sudheendra et al., 2015). In addition, yeast  cell 
walls possess phosphorylated mannosyl side chains, further enhancing their anionic surface charge 
(Lipke, Ovalle, 1998) that possibly helps the cationic hydrophobic surface of hBD-3 to bind and 
insert into the C. glabrata cell membrane (Maturana et al., 2017; Sudheendra et al., 2015). 
In conclusion, hBD-3 showed an inhibitory effect on fluconazole-resistant C. glabrata and 
a synergistic effect together with fluconazole. The combination of these two agents at 
concentrations that were inhibitory for C. glabrata, had no cytotoxicity towards human epithelial 
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cells and probably could be used as an adjunctive treatment in patients with C. glabrata infection. 
Nonetheless, future studies should investigate the mechanisms underlying these synergistic effects.   
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Table 1. Demographic data of 21 patients with C. glabrata infection  
Characteristics No. of patients (%) 
Mean age ± SD, years old (range) 69 ± 16.75 (17-97) 
Gender 
Male 15 (71.43) 
Female 6 (28.57) 
 
Table 2. Infection area distribution of Candida glabrata (21 episodes) 
Characteristics No. of episodes (%) 
Area 
Respiratory tract 15 (71.42) 
Skin and nail 3 (14.28) 
Urine 2 (9.52) 
Blood 1 (4.76) 
 
Table 3. Antifungal susceptibility tests of clinically isolated Candida glabrata (n=16) and a 
standard strain (ATCC 2001) 
Fungal isolates 
MIC (µg/ml) 
Fluconazole Caspofungin Amphotericin Ba 
Candida glabrata ATCC 2001 1 (S) 0.125 (S) 0.5 
1. Candida glabrata F2018C > 64 (R) 0.25 (I) 1 
2. Candida glabrata N7160 1 (S-DD) 0.25 (I) 0.5 
3. Candida glabrata W98278 0.5 (S-DD) 0.25 (I) 1 
4. Candida glabrata B46945 0.5 (S-DD) 0.25 (I) 0.5 
5. Candida glabrata B06048 0.25 (S-DD) 0.25 (I) 0.5 
20 
 
6. Candida glabrata T04267 1 (S-DD) 0.25 (I) 0.5 
7. Candida glabrata B03989 1 (S-DD) 0.25 (I) 0.25 
8. Candida glabrata F52615 8 (S-DD) 0.25 (I) 0.5 
9. Candida glabrata B5804 1 (S-DD) 0.25 (I) 0.25 
10. Candida glabrata S6169 1 (S-DD) 0.25 (I) 0.25 
11. Candida glabrata F3530 0.5 (S-DD) 0.25 (I) 0.25 
12. Candida glabrata B9392 8 (S-DD) 0.125 (S) 0.25 
13. Candida glabrata S3650 4 (S-DD) 0.125 (S) 0.25 
14. Candida glabrata S3304 4 (S-DD) 0.125 (S) 0.5 
15. Candida glabrata S5866 1 (S-DD) 0.125 (S) 0.5 
16. Candida glabrata S5843 1 (S-DD) 0.125 (S) 0.25 
a No Amphotericin B interpretive guidelines are available for testing of Candida species. 
S-DD; susceptible-dose dependent, S; susceptible, I; intermediate, R; resistant 
Table 4. Antifungal susceptibility tests of fluconazole and hBD-3 against randomly chosen 
Candida glabrata isolates 
Fungal isolates 
MIC (µg ml-1) MFC (µg ml-1) 
Fluconazole hBD-3a hBD-3 
Candida glabrata ATCC 2001 1 (S-DD) 50 50 
Candida glabrata F2018C > 64 (R) 50 75 
Candida glabrata S3304 4 (S-DD) 50 75 
Candida glabrata S3650 4 (S-DD) 75 >100 
Candida glabrata F52615 8 (S-DD) 50-75 >100 
 
a No hBD-3 interpretive guidelines are available for testing of Candida species. 





Figure 1. Demographic data of 307 episodes from 254 patients with candidiasis at KCMH in 2017. Isolated 







Figure 2. Checkerboard microdilution assay of hBD-3 and fluconazole against fluconazole-resistant 
C. glabrata F2018C. C. glabrata were incubated with combinations of fluconazole (2-128 μg ml-1) and 
hBD-3 (0.5-75 μg ml-1) for 24 h. Synergistic effect (black); Additive effect (dark grey), and No interaction 





Figure 3. Time-killing assay of hBD-3 alone and hBD-3 in combination with fluconazole against 
fluconazole-resistant C. glabrata isolate (F2018C). C. glabrata were incubated with fluconazole at 32 
μg/ml (dark gray square), hBD-3 at 25 μg ml-1 (light gray triangle), a combination of fluconazole and hBD-
3 (black triangle), and control or vehicle (black circle) for 24 h.  
 
Figure 4. Cytotoxicity of hBD-3 alone or hBD-3 in a combination with fluconazole on BEAS-2B cells. 
BEAS-2B cells were co-cultured with different concentrations of hBD-3 (25-100 μg ml-1) (a) or in a 
combination with fluconazole (b) at 37°C in a 5% CO2 incubator for 24 h. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001, Student’s t-test. ns: not significance 
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